全文获取类型
收费全文 | 7980篇 |
免费 | 543篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 319篇 |
妇产科学 | 156篇 |
基础医学 | 999篇 |
口腔科学 | 114篇 |
临床医学 | 768篇 |
内科学 | 1691篇 |
皮肤病学 | 112篇 |
神经病学 | 820篇 |
特种医学 | 365篇 |
外科学 | 1226篇 |
综合类 | 36篇 |
预防医学 | 557篇 |
眼科学 | 117篇 |
药学 | 580篇 |
中国医学 | 14篇 |
肿瘤学 | 649篇 |
出版年
2024年 | 14篇 |
2023年 | 96篇 |
2022年 | 122篇 |
2021年 | 203篇 |
2020年 | 174篇 |
2019年 | 221篇 |
2018年 | 271篇 |
2017年 | 238篇 |
2016年 | 218篇 |
2015年 | 267篇 |
2014年 | 338篇 |
2013年 | 437篇 |
2012年 | 623篇 |
2011年 | 627篇 |
2010年 | 321篇 |
2009年 | 302篇 |
2008年 | 498篇 |
2007年 | 509篇 |
2006年 | 515篇 |
2005年 | 423篇 |
2004年 | 420篇 |
2003年 | 384篇 |
2002年 | 381篇 |
2001年 | 59篇 |
2000年 | 45篇 |
1999年 | 64篇 |
1998年 | 78篇 |
1997年 | 58篇 |
1996年 | 60篇 |
1995年 | 57篇 |
1994年 | 50篇 |
1993年 | 48篇 |
1992年 | 43篇 |
1991年 | 37篇 |
1990年 | 27篇 |
1989年 | 32篇 |
1988年 | 22篇 |
1987年 | 27篇 |
1986年 | 27篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 35篇 |
1982年 | 21篇 |
1981年 | 21篇 |
1980年 | 11篇 |
1979年 | 12篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1975年 | 12篇 |
1967年 | 7篇 |
排序方式: 共有8575条查询结果,搜索用时 15 毫秒
31.
Per Jensen M.D. Søren Buus Jensen M.D. Per Soelberg Sørensen M.D. Birgitte D. Bjerre M.D. Dominick A. Rizzi M.D. Anne Stub Sørensen M.D. Rene Klysner M.D. Kim Brinch M.D. Bo Jespersen M.D. Henrik Nielsen M.D. 《Archives of sexual behavior》1990,19(1):1-14
Sexual dysfunction is a well-known complication of chronic somatic illness. Eighty-six consecutive epileptic outpatients, 38 men and 48 women, without accompanying disorders, were studied. The frequency and symptoms of sexual dysfunction were compared with results from previous studies using identical sexological methodology. The previous studies were of diabetic patients and healthy controls. Eight percent of the epileptic men reported a sexual dysfunction compared to 44% of the diabetics and 13% of the controls. Epileptic women, diabetic women, and controls showed no significant differences in sexual dysfunction (29%, 28%, and 25%, respectively). In both sexes, the sexual function measured by frequencies of coitus and masturbation was normal. Most patients had good control of epileptic attacks on a treatment of monotherapy. Hormonal status was generally within normal limits in both men and women; only a few minor differences were found and they showed no correlation with sexual dysfunction. Psychologically and socially the patients did not differ appreciably from normals, and they exhibited a high degree of disease acceptance. This study, using a biopsychosocial approach in understanding sexual dysfunctions, is in contrast with previous, mainly uncontrolled, studies of epileptic patients that reported high frequencies of hyposexuality in males. We conclude that epilepsy does not necessarily increase the risk of sexual dysfunction in male or female. 相似文献
32.
Henrik H Iversen Fredrik Celsing Anna M Leone Lars E Gustafsson N Peter Wiklund 《British journal of pharmacology》1997,120(4):702-706
- Nitric oxide (NO) has been suggested as a gastrointestinal neurotransmitter, mediating the gastric receptive relaxation and the relaxation in the peristaltic reflex. The aim of the present study was to measure nerve-induced NO formation in vivo in the gastrointestinal tract.
- Formation of the nitric oxide oxidation products nitrite and nitrate during vagal nerve stimulation were measured in the anaesthetized rabbit. Microdialysis probes were inserted into the wall of the stomach and proximal colon, and nitrite and nitrate in dialysate measured by capillary electrophoresis.
- During bilateral vagal nerve stimulation there was an increase in nitrite and nitrate formation at the level of the stomach and in nitrite formation at the level of the colon. This increase was inhibited by intravenous administration of the NO synthase inhibitor Nω-nitro-L-arginine methyl ester (L-NAME 30 mg kg−1). Furthermore, L-NAME significantly increased nerve-induced gastric and colonic contractions, as well as spontaneous colonic contractions.
- In summary, we present a new methodological procedure for quantification of small changes in nitric oxide formation in vivo. This study provides evidence that nitric oxide is released in the stomach and colonic wall during vagal nerve activity, at concentrations able to cause inhibition of smooth muscle contractions in vivo.
33.
34.
Lue?en Henrik. L. de Leeuw Bas. J. Langeme?er Mariska W. E. de Boer A. G. Verhoef J. Coos. Junginger Hans E. 《Pharmaceutical research》1996,13(11):1668-1672
Purpose. To evaluate the effect of the crosslinked poly(acrylate) carbomer 934P (C934P) and its freeze-dried neutralized sodium salt (FNaC934P) as well as chitosan hydrochloride on the intestinal absorption of the peptide drug buserelin.
Methods. Buserelin was applied intraduodenally in control buffer, 0.5% (w/v) C934P, 0.5% (w/v) FNaC934P, 1.5% (w/v) chitosan hydrochloride or FNaC934P/chitosan hydrochloride (1:1 (v/v)) mixture in rats.
Results. All polymer preparation showed a statistically significant improvement of buserelin absorption compared to the control solution. The absolute bioavailabilities for the different polymer preparations were: control, 0.1%; 0.5% FNaC934P, 0.6%; 0.5% C934P, 2.0%; chitosan hydrochloride, 5.1% and FNaC934P/chitosan hydrochloride (1:1 (v/v)) mixture, 1.0%. The higher bioavailability with chitosan hydrochloride compared to C934P and FNaC934P indicates that for buserelin the intestinal transmucosal transport enhancing effect of the polymer plays a more dominant role than the protection against proteases such as -chymotrypsin.
Conclusions. The mucoadhesive polymers carbomer 934P and chitosan hydrochloride are able to enhance the intestinal absorption of buserelin in vivo in rats, and may therefore be promising excipients in peroral delivery systems for peptide drugs. 相似文献
35.
Horváth G Stotz G Tolvaj G Osztrogonácz H Dávid K 《Pathology oncology research : POR》1996,2(1-2):59-62
The results of 43 interferon treatments of 35 patients (23 male, 12 female) are reported. The duration of the treatment was
6–18 months, the dose of interferon was 3x3-5 MU weekly. Complete response (HCV RNA became negative) was found in 11, relapse
was observed in 3 patients. Partial response (transaminase levels became normal, or less than twice normal value, but patients
remained HCV RNA positive) occurred in 23 cases, relapse was obeserved in 16. The therapy had no effect in 9 cases. The higher
dose and longer term interferon therapy resulted in a higher rate of response to the treatment and a reduction in the number
of relapses.
This work was supported by the Hungarian Ministry of Welfare (No. T-10 064/93). 相似文献
36.
Henrik Gren Kourosh Lotfi Anna‐Lena Zackrisson Curt Peterson 《Basic & clinical pharmacology & toxicology》2003,93(6):297-304
Abstract: Increased expression of P‐glycoprotein encoded by the mdr‐1 gene is a well‐characterised mechanism for resistance to cancer chemotherapeutic drugs in cell lines. However, the P‐glycoprotein expression after removal of the selection pressure has not fully been elucidated. The stability of P‐glycoprotein expression in the presence (+) and absence (?) of vincristine (30 or 150 nM) was studied in multidrug resistant K562 cell lines (VCR30+, VCR150+, VCR30? and VCR150?) for 11 months. The P‐glycoprotein protein and mdr‐1 mRNA levels were determined at regular intervals using flow cytometry and real‐time PCR, respectively. Chemosensitivity to a panel of antineoplastic drugs was measured using an MTT assay. The presence of vincristine (VCR30+ and VCR150+) resulted in high and stable levels of P‐glycoprotein and mdr‐1 mRNA during the whole period compared to wild type. As for the VCR30? and VCR150? subcultures, the expressions of P‐glycoprotein and mdr‐1 mRNA were stable for five months, and then the levels decreased rapidly. Concomitantly, the sensitivity to drugs known as P‐glycoprotein substrates was restored. In conclusion, resistant cells growing in the presence of the inducing drug have a stable P‐glycoprotein expression and resistance level, but removing the inducing drug may result in a sudden and rapid lowering of P‐glycoprotein and mdr‐1 mRNA levels as long as five months after drug withdrawal. 相似文献
37.
Stephen F Stanziale Henrik Petrowsky Prasad S Adusumilli Leah Ben-Porat Mithat Gonen Yuman Fong 《Clinical cancer research》2004,10(9):3225-3232
PURPOSE: The antitumor efficacy of a herpes simplex virus (HSV)-1 oncolytic virus depends on the cytotoxic effect of the virus, but also on viral replication and spread within the tumor. Apoptosis is considered a defense mechanism of infected cells that minimizes the spread of viral progeny by limiting cellular production of virus. We sought to determine whether oncolytic HSV-1 infection induces apoptosis in neighboring, uninfected cells and whether manipulation of apoptosis can increase viral replication and cytotoxicity. EXPERIMENTAL DESIGN: NV1066 is an oncolytic HSV-1 mutant that contains the marker gene for enhanced green fluorescent protein. OCUM human gastric cancer cells were infected with NV1066 in vitro and inspected for apoptosis by Hoechst and terminal deoxynucleotidyltransferase-mediated nick end labeling staining and for infection by expression of green fluorescence. RESULTS: A significant increase in apoptosis was seen in cells infected by NV1066. More interestingly, a significant percentage (10%) of uninfected cells also proceeded to apoptosis. After NV1066 infection, cells were also treated with N-acetylcysteine (NAC), an inhibitor of apoptosis. By day 4 after infection, 2.7x more NV1066 was produced in cells exposed to NAC than in those not exposed to NV1066 (P = 0.04). NAC also increased tumor kill when administered with virus. CONCLUSIONS: These data suggest that NV1066 induces apoptosis in uninfected cocultured cells, potentially hindering propagation of viral progeny and concomitant tumor kill. Inhibition of apoptosis may improve the efficacy of oncolytic HSV-1 therapy. 相似文献
38.
39.
Fredrik Wiklund Bj?rn-Anders Jonsson Anthony J Brookes Linda Str?mqvist Jan Adolfsson Monica Emanuelsson Hans-Olov Adami Katarina Augustsson-B?lter Henrik Gr?nberg 《Clinical cancer research》2004,10(21):7150-7156
PURPOSE: The RNASEL gene has been proposed as a candidate gene for the HPC1 locus through a positional cloning and candidate gene approach. Cosegregation between the truncating mutation E265X and disease in a hereditary prostate cancer (HPC) family and association between prostate cancer risk and the common missense variant R462Q has been reported. To additionally evaluate the possible role of RNASEL in susceptibility to prostate cancer risk, we performed a comprehensive genetic analysis of sequence variants in RNASEL in the Swedish population. EXPERIMENTAL DESIGN: Using 1624 prostate cancer cases and 801 unaffected controls, the truncating mutation E265X and five common sequence variants, including the two missense mutations R462Q and D541E, were evaluated for association between genotypes/haplotypes and prostate cancer risk. RESULTS: The prevalence of E265X carriers among unaffected controls and prostate cancer patients was almost identical (1.9 and 1.8% in controls and cases, respectively), and evidence for segregation of E265X with disease was not observed within any HPC family. Overall, the analyses of common sequence variants provided limited evidence for association with prostate cancer risk. We found a marginally significant inverse association between the missense mutation D541E and sporadic prostate cancer risk (odds ratio, 0.77; 95% confidence interval, 0.59-1.00) and reduced risk of prostate cancer in carriers of two different haplotypes being completely discordant. CONCLUSIONS: Considering the high quality in genotyping and the size of this study, these results provide solid evidence against a major role of RNASEL in prostate cancer etiology in Sweden. 相似文献
40.
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. 总被引:12,自引:0,他引:12
Eleftherios P Diamandis Andreas Scorilas Stefano Fracchioli Marleen Van Gramberen Henk De Bruijn Alfthan Henrik Antoninus Soosaipillai Linda Grass George M Yousef Ulf-Hakan Stenman Marco Massobrio Ate G J Van Der Zee Ignace Vergote Dionyssios Katsaros 《Journal of clinical oncology》2003,21(6):1035-1043
PURPOSE: The discovery of new ovarian cancer biomarkers that are suitable for early disease diagnosis and prognosis may ultimately lead to improved patient management and outcomes. PATIENTS AND METHODS: We measured, by immunoassay, human kallikrein 6 (hK6) concentration in serum of 97 apparently healthy women, 141 women with benign abdominal diseases, and 146 women with histologically proven primary ovarian carcinoma. We then calculated the diagnostic sensitivity and specificity of this test and examined the association of serum hK6 concentration with various clinicopathologic variables and patient survival. RESULTS: Serum hK6 concentration between normal and benign disease patients was not different (mean, 2.9 and 3.1 micro g/L, respectively). However, hK6 in presurgical serum of ovarian cancer patients was highly elevated (mean, 6.8 micro g/L; P <.001). Serum hK6 decreased after surgery (to a mean of 3.9 micro g/L) in 68% of patients. The diagnostic sensitivity of serum hK6 at 90% and 95% specificity is 52% and 47%, respectively, in the whole patient population. For early stage disease (stage I or II), sensitivity is approximately 21% to 26%. When combined with CA-125, at 90% specificity, sensitivity increases to 72% (for all patients) and to 42% in stage I or II disease. Serum hK6 concentration correlates moderately with CA-125 and is higher in patients with late-stage, higher-grade disease and in patients with serous histotype. Preoperative serum hK6 concentration is a powerful predictor of disease-free and overall survival in both univariate and multivariate analyses. CONCLUSIONS: Serum hK6 concentration seems to be a new biomarker for ovarian carcinoma and may have value for disease diagnosis and prognosis. 相似文献